Xspray Pharma gets product patents for HyNap-Sora and HyNap-Nilo approved in the United States

STOCKHOLM – Xspray Pharma has received approval for two applied patents in the United States. The patent comprises the composition regarding the product candidates HyNap-Sora and HyNap-Nilo. These are Xspray’s second and third product patents in a short time span to be approved on the main market in the United States. The Company previously announced that a patent for HyNap-Dasa has been approved in Japan and the United States, and have ongoing pending applications for several corresponding patents in Japan and Europe among others.

“We now have approved patents in the United States that cover the three products we intend to introduce onto the American market when the original substance patents have expired (during the period 2020-2023). We have systematically and strategically been working with our innovations both in order to realize them into products, and also to secure the value through a satisfactory patent protection. I regard this as a verification of those efforts,” says Per Andersson, CEO, Xspray Pharma.

Xspray Pharma has received a notice of allowance for two patents in the United States regarding the product candidates HyNap-Sora and HyNap-Nilo, both of which are intended for the treatment of certain forms of cancer. These are Xspray’s second and third product patents that are approved on the most important market, the United States. The announcement comes in conjunction with the Company plan to apply for and receive patents regarding composition and method for the three product candidates being under development for the three most important markets, the United States, Europe and Japan.

“We have with these patents, coupled with the positive results from our recently announced clinical study, taken important steps towards the goal of developing our first three products for launch onto the American market,” comments Xspray CEO Per Andersson.

Xspray Pharma’s shares were introduced on Nasdaq First North September 28 after a successful new rights issue which added SEK 132 million before issue expenses. The plan now is to use the capital for developing three product candidates and future cancer drugs based on the Company’s in-house developed technology, as well as introducing the first products onto the American market during the period 2020-2023.

 

For further information, please contact:

Per Andersson, CEO, Xspray Pharma AB (publ)
Mobile: +46 (0)706 88 23 48
E-mail: per.andersson@xspray.com

About Xspray Pharma                                

Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. Xspray uses its innovative RightSize-technology in order to develop improved and generic versions of already marketed cancer drugs, primarily protein kinase inhibitors (PKI), for treating cancer. The segment is the second largest within the oncology department and the drug prices are very high. Through its innovative technology, Xspray can enter the market as first competitor to the original drugs available today without the hindrance of secondary patents. Xspray’s goal is to ha three products ready for launch on the American market during the period 2020-2023, with a first product launched at the latest by 2021. The company has patents on production technology, equipment and the resulting products. The shares in Xspray Pharma (publ) are traded on Nasdaq First North Stockholm and Redeye is the Certified Adviser for the company.

 

This information is information that Xspray Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at the above stated time.

 

Xspray Pharma AB (publ)

Gunnar Asplunds Allé 326

171 63 Solna

www.xspray.com